| 000 | 01911 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250513143818.0 | ||
| 264 | 0 | _c19980616 | |
| 008 | 199806s 0 0 eng d | ||
| 022 | _a0959-8049 | ||
| 024 | 7 |
_a10.1016/s0959-8049(97)10011-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCastiglione-Gertsch, M | |
| 245 | 0 | 0 |
_aRetreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. _h[electronic resource] |
| 260 |
_bEuropean journal of cancer (Oxford, England : 1990) _cDec 1997 |
||
| 300 |
_a2321-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTamoxifen _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aTattersall, M | |
| 700 | 1 | _aHacking, A | |
| 700 | 1 | _aGoldhirsch, A | |
| 700 | 1 | _aGudgeon, A | |
| 700 | 1 | _aGelber, R D | |
| 700 | 1 | _aLindtner, J | |
| 700 | 1 | _aCoates, A | |
| 700 | 1 | _aCollins, J | |
| 700 | 1 | _aIsley, M | |
| 700 | 1 | _aSenn, H J | |
| 700 | 1 | _aRudenstam, C M | |
| 773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 33 _gno. 14 _gp. 2321-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0959-8049(97)10011-9 _zAvailable from publisher's website |
| 999 |
_c9582825 _d9582825 |
||